Zhejiang Huahai Pharmaceutical Co., Ltd. 2025 annual performance reduction announcement
Securities code: 600521 Securities abbreviation: Huahai Pharmaceutical Announcement number: Lin 2026-005
Bond code: 110076 Bond abbreviation: Huahai Convertible Bonds
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Important content reminder:
According to preliminary calculations by the financial department, Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is expected to achieve a net profit attributable to shareholders of the listed company between 224 million yuan and 335 million yuan in 2025. Compared with the same period last year (statutory disclosure data), it will decrease by approximately 783.98 million yuan to 894.98 million yuan, a year-on-year decrease of approximately 70% to 80%.
The company's net profit attributable to shareholders of listed companies in 2025, excluding non-recurring gains and losses, is expected to be at
Between 113 million yuan and 226 million yuan, compared with the same period last year (statutory disclosure data), it will decrease by approximately 903.32 million yuan to 1016.32 million yuan, a year-on-year decrease of approximately 80% to 90%.
1. Performance forecast for this period
(1) Performance forecast period
From January 1, 2025 to December 31, 2025.
(2) Performance forecast
According to preliminary calculations by the financial department, the company's net profit attributable to shareholders of listed companies in 2025 is expected to be between 224 million yuan and 335 million yuan. Compared with the same period last year (statutory disclosure data), it will decrease by approximately 783.98 million yuan to 894.98 million yuan, a year-on-year decrease of approximately 70% to 80%.
The company's net profit attributable to shareholders of listed companies in 2025, excluding non-recurring gains and losses, is expected to be at
Between 113 million yuan and 226 million yuan, compared with the same period last year (statutory disclosure data), it will decrease by approximately 903.32 million yuan to 1016.32 million yuan, a year-on-year decrease of approximately 80% to 90%.
2. Performance of the same period last year
1/2
(1) Net profit attributable to shareholders of listed companies: 1,118.98 million yuan. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses: 1,129.32 million yuan.
(2) Earnings per share: 0.77 yuan.
3. Main reasons for changes in performance in this period
During the reporting period, the company's net profit attributable to shareholders of listed companies and net profit after non-recurring gains and losses attributable to shareholders of listed companies decreased significantly compared with the same period last year, mainly due to:
Domestic preparation business: With the expansion and deepening of the domestic centralized purchasing policy, prices continue to be under pressure and competition has further intensified; at the same time, the market competition for the company's old product stock has intensified, and it will take time to ramp up new products, which in turn has led to a year-on-year decline in domestic preparation sales revenue, affecting a year-on-year decrease in profits;
The API industry continues to face fierce competition intertwined with overcapacity and price pressure. At the same time, new products have long development cycles and are greatly affected by changes in internal and external operating environments. The industrialization of new projects has not met expectations, which has jointly affected the year-on-year decline in sales revenue of APIs and the year-on-year decrease in profits;
The company accelerated the progress of the research and development project of innovative biological drugs, and the corresponding research and development investment increased significantly year-on-year. During the reporting period, the company's non-operating profits and losses increased by approximately 100 million yuan to 130 million yuan year-on-year, mainly due to the increase in gains from changes in fair value recognized in the current period for financial assets measured at fair value and changes included in current profits and losses, and gains from the sale of part of equity.
4. Risk warning
The company has no major uncertain factors that affect the accuracy of this performance forecast.
5. Other explanations
This performance forecast data is only preliminary accounting data and has not been audited by an accounting firm. The specific and accurate financial data shall be based on the company's officially disclosed 2025 annual report. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Zhejiang Huahai Pharmaceutical Co., Ltd. January 26, 2026
2/2